Angiotensin II regulates choroid plexus blood flow by interacting with the sympathetic nervous system and nitric oxide

Brain Res. 1999 Jan 23;816(2):518-26. doi: 10.1016/s0006-8993(98)01220-7.

Abstract

Blood flow to the rat choroid plexus has minimal variability when plasma angiotensin II (AII) concentration is changed within a broad range of levels. We tested the hypothesis that a complex interplay of the vasoconstrictor and vasodilator AII actions in choroidal tissue results in small net changes in choroidal blood flow. Blood flow was measured with 123I- or 125I-N-isopropyl-p-iodoamphetamine. AII was infused intravenously (i.v.) at 30 (moderate dose) and 300 ng kg-1 min-1 (high dose), which respectively decreased (15%) and did not change choroidal blood flow. To determine whether AII regulates choroidal blood flow by interacting with the sympathetic nervous system, rats were given phentolamine (1 mg kg-1, i.v.). This alpha-adrenoceptor antagonist by itself did not alter blood flow; however, it attenuated the blood flow-lowering effect of moderate AII dose. Phentolamine also unmasked the vasodilator AII actions at high peptide concentration. beta-Adrenoceptor blockade, with propranolol (1 mg kg-1, i.v.), reduced blood flow (18-20%) and increased vascular resistance (23-26%). During beta-adrenoceptor blockade, a further decrease in blood flow (15-21%) and increase in vascular resistance (23%) was noted when high AII dose was administered. The direct vasoconstrictor effect of AII at moderate dose on choroidal vasculature was examined in rats subjected to chronic bilateral superior cervical ganglionectomy. In these animals, AII decreased blood flow (24%) and increased vascular resistance (24%). To find out whether the hemodynamic AII actions in choroidal tissue are mediated by nitric oxide (NO), Nomega-nitro-l-arginine methyl ester (l-NAME) was used. l-NAME (0.1 mg kg-1, i.v.) by itself did not alter blood flow; however, in l-NAME-treated rats high AII dose lowered blood flow (25-32%) and increased vascular resistance (30-43%). We conclude that the vasoconstrictor AII actions involve a direct peptide effect on the choroidal vascular bed, and the AII-mediated potentiation of sympathetic activity, which results in the activation of alpha-adrenoceptors. The AII-mediated stimulation of sympathetic nerves also results in the beta-adrenoceptor-dependent relaxation of choroidal blood vessels. In addition, choroidal vasodilatory actions of AII are NO-mediated.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adrenergic alpha-Antagonists / pharmacology
  • Angiotensin II / pharmacology*
  • Animals
  • Choroid Plexus / blood supply
  • Choroid Plexus / drug effects*
  • Enzyme Inhibitors / pharmacology
  • Ganglionectomy
  • Infusions, Intravenous
  • Male
  • NG-Nitroarginine Methyl Ester / pharmacology
  • Rats
  • Rats, Sprague-Dawley
  • Regional Blood Flow
  • Superior Cervical Ganglion / physiology
  • Sympathetic Nervous System / drug effects*
  • Vasoconstrictor Agents / pharmacology*
  • Vasodilator Agents / pharmacology*

Substances

  • Adrenergic alpha-Antagonists
  • Enzyme Inhibitors
  • Vasoconstrictor Agents
  • Vasodilator Agents
  • Angiotensin II
  • NG-Nitroarginine Methyl Ester